Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT06627179 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT06627179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06627179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Lead sponsor
Laboratoires Thea
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 11, 2024
Completion date
July 31, 2028
Enrollment
81 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

deaf blind, eye diseases, hereditary, eye disorders congenital, retinal disease, retinitis pigmentosa (rp), usher syndrome type 2, vision disorders